Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ARQL - ArQule Inc.

Previous close
20
0   0%

Share volume: 0
Last Updated: Wed 15 Jan 2020 06:00:00 AM CET
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%
$20.00
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
24%
Profitability 36%
Dept financing 14%
Liquidity 23%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$20.00
P/E Ratio 
N/A
DAY RANGE
$20.00 - $20.00
EPS 
-$0.34
52 WEEK RANGE
$3.15 - $20.45
52 WEEK CHANGE
$429.10
MARKET CAP 
2.416 B
YIELD 
N/A
SHARES OUTSTANDING 
120.788 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$108,709,321
AVERAGE 10 VOLUME 
$4,806,748
AVERAGE 30 VOLUME 
$7,051,305
Company detail
CEO: Paolo Pucci
Region: US
Website: http://www.arqule.com
Employees: 36
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751 and Derazantinib products. The company was founded in 1993 and is headquartered in Burlington, MA.

Recent news